NASDAQ:ENSC

Ensysce Biosciences Stock Forecast, Price & News

$7.00
0.00 (0.00 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.39
$7.10
50-Day Range N/A
52-Week Range
$6.39
$23.99
Volume13,604 shs
Average Volume10,154 shs
Market Capitalization$43.54 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.3
30 days | 90 days | 365 days | Advanced Chart
Receive ENSC News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.


About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.33 out of 5 stars

Medical Sector

1891st out of 2,214 stocks

Pharmaceutical Preparations Industry

778th out of 867 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ensysce Biosciences (NASDAQ:ENSC) Frequently Asked Questions

What stocks does MarketBeat like better than Ensysce Biosciences?

Wall Street analysts have given Ensysce Biosciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ensysce Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ensysce Biosciences' next earnings date?

Ensysce Biosciences is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Ensysce Biosciences
.

Who are Ensysce Biosciences' key executives?

Ensysce Biosciences' management team includes the following people:
  • Dr. D. Lynn Kirkpatrick, CEO & Director (Age 64)
  • Mr. David C. Humphrey, Chief Financial Officer (Age 51)
  • Dr. Jeffrey Millard, Chief Operating Officer
  • Mr. Richard Wright M.B.A., MSE, Chief Bus. Officer
  • Mr. Geoff Birkett, Chief Commercial Officer
  • Dr. William K. Schmidt, Chief Medical Officer (Age 70)

Who are some of Ensysce Biosciences' key competitors?

What is Ensysce Biosciences' stock symbol?

Ensysce Biosciences trades on the NASDAQ under the ticker symbol "ENSC."

How do I buy shares of Ensysce Biosciences?

Shares of ENSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ensysce Biosciences' stock price today?

One share of ENSC stock can currently be purchased for approximately $7.00.

How much money does Ensysce Biosciences make?

Ensysce Biosciences has a market capitalization of $43.54 million.

What is Ensysce Biosciences' official website?

The official website for Ensysce Biosciences is ensysce.com.

Where are Ensysce Biosciences' headquarters?

Ensysce Biosciences is headquartered at 250 WEST 57 TH STREET SUITE 415, NEW YORK NY, 10107.

How can I contact Ensysce Biosciences?

Ensysce Biosciences' mailing address is 250 WEST 57 TH STREET SUITE 415, NEW YORK NY, 10107. The company can be reached via phone at 858-263-4196.


This page was last updated on 7/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.